Open AccessLong‐term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow‐up
Author(s) -
Dreyling Martin,
Goy Andre,
Hess Georg,
Kahl Brad S.,
HernándezRivas JoséÁngel,
Schuier Natasha,
Qi Keqin,
Deshpande Sanjay,
Zhu Angeline,
Parisi Lori,
Wang Michael L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000712
Subject(s) - ibrutinib , medicine , chemoimmunotherapy , mantle cell lymphoma , oncology , refractory (planetary science) , clinical trial , progression free survival , lymphoma , chemotherapy , rituximab , leukemia , chronic lymphocytic leukemia , physics , astrobiology